Several brokerages have updated their recommendations and price targets on shares of Citigroup (NYSE: C) in the last few weeks: 10/14/2026 – Citigroup was given a new $148.00 price target by UBS Group AG. 10/14/2026 – Citigroup had its price target lowered by TD Cowen from $150.00 to $148.00. They now have a “buy” rating […]

Several brokerages have updated their recommendations and price targets on shares of AppLovin (NASDAQ: APP) in the last few weeks: 10/14/2026 – AppLovin had its price target lowered by The Goldman Sachs Group, Inc. from $465.00 to $400.00. They now have a “neutral” rating on the stock. 10/14/2026 – AppLovin had its price target lowered […]

A number of research firms have changed their ratings and price targets for FirstCash (NASDAQ: FCFS): 10/15/2026 – FirstCash had its price target raised by Canaccord Genuity Group Inc. from $252.00 to $265.00. They now have a “buy” rating on the stock. 10/10/2026 – FirstCash was downgraded by Wall Street Zen from “buy” to “hold”. […]

A number of research firms have changed their ratings and price targets for Hilton Grand Vacations (NYSE: HGV): 10/15/2026 – Hilton Grand Vacations had its price target lowered by Susquehanna from $50.00 to $39.00. They now have a “neutral” rating on the stock. 10/8/2026 – Hilton Grand Vacations is now covered by JPMorgan Chase & […]

GE Vernova (NYSE: GEV) has recently received a number of price target changes and ratings updates: 10/14/2026 – GE Vernova had its price target lowered by Susquehanna from $1,300.00 to $1,270.00. They now have a “positive” rating on the stock. 10/13/2026 – GE Vernova had its “buy” rating reaffirmed by Guggenheim. They now have a […]

PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates: 10/16/2026 – PTC Therapeutics is now covered by Truist Financial Corporation. They set a “hold” rating and a $62.00 price target on the stock. 10/15/2026 – PTC Therapeutics had its “buy” rating reaffirmed by UBS Group AG. They now […]

PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) VP Mark Boulding sold 192 shares of the stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $64.26, for a total transaction of $12,337.92. Following the sale, the vice president directly owned 105,272 shares of the company’s […]

Stock analysts at Truist Financial assumed coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research note issued on Friday, Briefing.com reports. The brokerage set a “hold” rating and a $62.00 price target on the biopharmaceutical company’s stock. Truist Financial’s price objective indicates a potential upside of 1.66% from the stock’s […]